<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 14, 1999
PHARMERICA, INC.
(Exact name of Registrant as specified in its charter)
Delaware 0-20606 11-2310352
- ---------------------------- ------------------------ ----------------------
(State or other jurisdiction (Commission file Number) (Employer
of incorporation) Identification Number)
175 Kelsey Lane, Tampa, Florida 33619
- --------------------------------------------------------------------------------
(Address of principal executive offices)
(813) 626-7788
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 5. OTHER EVENTS.
On April 16, 1999, PharMerica, Inc. and Bergen Brunswig Corporation
announced that Bergen and PharMerica were named as defendants in a lawsuit
commenced on April 14, 1999 by PMR Corp. in the Superior Court of California,
San Diego County. The complaint seeks, among other things, an injunction
enjoining Bergen from closing its proposed acquisition of PharMerica and
general, special and punitive damages relating to alleged breaches of an
agreement between PMR and a Bergen subsidiary.
Bergen and PharMerica believe that PMR's claims are without merit
and intend to vigorously contest the allegations in PMR's complaint. A hearing
with respect to PMR's request for injunctive relief has been scheduled for April
20, 1999.
Statements in this press release regarding future events constitute
forward-looking statements under the Private Securities Litigation Reform Act of
1995. Forward-looking statements contained in this press release are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those implied by such forward-looking statements. For example,
because of the uncertainty of all litigation, there can be no assurance that
Bergen and PharMerica will be successful defending against PMR's lawsuit.
Certain additional risks associated with PharMerica and Bergen are set forth in
reports that they have filed with the Securities and Exchange Commission,
including Bergen's Annual Report on Form 10-K for the year ended September 30,
1998 and PharMerica's Annual Report on Form 10-K for the year ended December 31,
1998.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMERICA, INC.
By: /s/ David Redmond
---------------------------------------
David Redmond
Chief Financial Officer
Date: April 19, 1999
3
